knowledge -WSS

knowledge

author：focus 2025-09-30 12:17:21 - browse：4425

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： STAT Virtual Event: Putting AI to the Test

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

How Vertex's cystic fibrosis drug is changing patients' lives

ADA: All diabetes patients should be screened for liver condition

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Senate HELP committee spars over health care workforce policies

ChatGPT in medicine: STAT answers readers' burning questions

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Tori Bowie and the unacceptable rates of Black maternal death

Ukraine and a new approach to mental health in war

Heart attack and stroke risk calculators need revising

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Wildfire smoke exposes gaps in outdoor worker protections

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

hotspot

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

FDA panel to weigh approval of NurOwn, controversial ALS drug

Why are Kaiser Permanente staff considering a strike?

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Eating disorder hotline's move to chatbot carried cost for volunteers

Wikipedia

hotspot

leisure time

leisure time